📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
63 announcements match the current filters (relevance ≥ 5).
Neogen Chemicals approves Rs 600 Cr fundraise and sets Aug 13 as dividend record date
Neogen Chemicals' board has granted in-principle approval to raise up to Rs 600 crore through equity or other instruments, representing approximately 11% of its current market capitalization. The company also finalized August 13, 2026, as the record date for the FY26 final dividend. Additionally, its subsidiary, Neogen Morita New Materials, is seeking to increase its borrowing limit to Rs 500 crore. While Q1 FY27 results were approved, specific financial figures were not detailed in this summary document.
Confidence: HIGH
What changedThe company has initiated a major capital-raising process and formalized its dividend and AGM timelines.
Why it mattersA Rs 600 crore fundraise is significant relative to the company's TTM revenue of Rs 862 crore, signaling aggressive growth plans in the Lithium-ion battery sector or potential debt restructuring.
Proposed Fundraise: Rs 600 CrFundraise vs Market Cap: ~11%Subsidiary Borrowing Limit: Rs 500 CrDividend Record Date: August 13, 2026AGM Date: August 21, 2026
📅 Short termThe fundraise approval and dividend timeline are likely to support positive sentiment in the coming weeks.
📈 Long termThe capital infusion and increased borrowing capacity for the subsidiary align with the company's FY28 revenue target of Rs 1,150 crore, focusing on high-growth battery chemicals.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Equity dilution risk from the Rs 600 Cr fundraise
- High debt-to-equity ratio of 0.86 prior to fundraise
Key Highlights
Approved fundraise of up to Rs 600 crore via QIP or other permissible modes
Set August 13, 2026, as the record date for final dividend eligibility
Subsidiary Neogen Morita New Materials to increase borrowing powers to Rs 500 crore
37th Annual General Meeting (AGM) scheduled for August 21, 2026
Appointed CNK & Associates as Internal Auditors for FY 2026-27
👀 What to Watch
Investors should monitor the upcoming Q1 FY27 detailed financial statement and the specific deployment plan for the Rs 600 crore fundraise, particularly regarding the battery chemicals expansion.
CRISIL Downgrades Neogen Chemicals to 'A-/Negative' on Project Delays
CRISIL has downgraded the long-term credit rating of Neogen Chemicals from 'A' to 'A-' and its subsidiary, Neogen Ionics, from 'A-' to 'BBB+', both with a Negative outlook. The downgrade is driven by delays in the company's battery chemicals project and the slow receipt of insurance claims related to the Dahej plant fire (₹14.1 Cr). Total bank facilities rated across the group amount to ₹1,830 Cr, which is approximately 2.12x the company's TTM revenue of ₹862 Cr. This rating action reflects heightened execution risks and potential liquidity pressure.
Confidence: HIGH
What changedCRISIL lowered the credit ratings for both Neogen Chemicals and its subsidiary Neogen Ionics, maintaining a Negative outlook.
Why it mattersThe downgrade signals increased execution risk in the company's EV battery chemical pivot and may lead to higher borrowing costs on its ₹736 Cr debt, potentially impacting net margins which are already thin at 3.4% (TTM).
Total Rated Facilities (Group): ₹1,830 CrRated Facilities vs TTM Revenue: 212.3%Pending Insurance Claim: ₹14.1 CrParent Long-Term Rating: CRISIL A-/NegativeSubsidiary Long-Term Rating: CRISIL BBB+/Negative
📅 Short termNegative sentiment is expected as the market reacts to the formal acknowledgment of project delays and the potential for increased financing costs.
📈 Long termThe structural shift toward battery chemicals is facing teething issues; long-term recovery depends on the timely commissioning of the Dahej SEZ plant and stabilization of the lithium-ion supply chain.
⚠ Risk flags
- Project execution delays
- Liquidity strain from delayed insurance claims
- High debt relative to current revenue
- Negative rating outlook
Key Highlights
Long-term rating for Neogen Chemicals downgraded from CRISIL A/Negative to CRISIL A-/Negative.
Subsidiary Neogen Ionics downgraded from CRISIL A-/Negative to CRISIL BBB+/Negative.
Total bank facilities rated across the group stand at ₹1,830 Cr (₹680 Cr parent, ₹1,150 Cr subsidiary).
Downgrade attributed to delays in the battery chemicals project and pending insurance claims of ₹14.1 Cr.
Short-term rating for the parent company revised from CRISIL A1 to CRISIL A2+.
👀 What to Watch
Investors should monitor the revised commissioning timeline for the battery chemicals project and the Dahej plant rebuild, currently slated for FY27. Watch for potential increases in interest expenses in upcoming quarterly results due to the higher risk premium associated with the downgrade.
CRISIL Downgrades Neogen Chemicals to 'A-/Negative' on Project Delays
CRISIL has downgraded Neogen Chemicals' long-term rating from 'A' to 'A-' and its subsidiary Neogen Ionics from 'A-' to 'BBB+', maintaining a 'Negative' outlook. The downgrade impacts a total of ₹1,830 crore in bank facilities and ₹200 crore in NCDs. The rating action is driven by delays in the company's critical battery chemicals project and a lag in receiving insurance claims related to the Dahej plant fire. This reflects increased execution risk for a company currently trading at a high P/E of 199.8.
Confidence: HIGH
What changedCRISIL lowered the credit ratings for both the parent company and its wholly-owned subsidiary, Neogen Ionics, while maintaining a Negative outlook.
Why it mattersA credit downgrade typically leads to higher interest expenses and signals to the market that the company's aggressive expansion into EV battery chemicals is facing execution and liquidity hurdles.
Total Rated Bank Facilities: ₹1,830 CrRated NCDs: ₹200 CrRated Debt vs TTM Revenue: 235.5%Insurance Claim (Exceptional Item): ₹14.1 CrCurrent Debt-to-Equity: 0.86
📅 Short termThe downgrade is likely to put downward pressure on the stock price in the near term, especially given the high valuation and the 'Negative' outlook from the rating agency.
📈 Long termThe structural growth story depends on the successful ramp-up of the Lithium-ion battery segment; persistent delays could jeopardize the FY28 revenue target of ₹1,150 crore.
⚠ Risk flags
- Project execution delays
- Liquidity strain from delayed insurance claims
- High valuation (P/E 199.8) relative to earnings growth
- Increased cost of debt
Key Highlights
Long-term rating for Neogen Chemicals downgraded to CRISIL A-/Negative from CRISIL A/Negative.
Subsidiary Neogen Ionics Limited rating downgraded to CRISIL BBB+/Negative for ₹1,150 crore in facilities.
Total bank facilities and NCDs under review amount to ₹2,030 crore, which is ~235% of TTM revenue.
Downgrade rationale cites delays in the battery chemicals project and the ₹14.1 crore insurance claim settlement.
Short-term rating for the parent company also downgraded from CRISIL A1 to CRISIL A2+.
👀 What to Watch
Investors should monitor the execution timeline for the battery chemicals project and the Dahej plant rebuild, currently planned for FY27. Watch for the impact of higher borrowing costs on net margins, which are already thin at 3.4% (TTM).
₹155 Cr Total Insurance Received; Neogen Updates on Dahej Fire Recovery and H1FY27 Rebuild
Neogen Chemicals has received an additional ₹15 crore as a fourth on-account insurance payment for the March 2025 Dahej fire, bringing total receipts to ₹155 crore. The company has recognized a total consolidated loss of ₹362.90 crore, representing approximately 42% of its TTM revenue, though it expects to recover ₹348.82 crore through insurance. Production at the affected MPP3 facility remains suspended, with a replacement plant currently under construction and scheduled for commissioning in H1FY27. To mitigate business disruption, the company has shifted critical production to other sites and is leveraging its Patancheru plant expansion.
Confidence: HIGH
What changedThe company received a fresh ₹15 crore tranche of insurance money and provided a concrete H1FY27 timeline for the restoration of its Dahej facility.
Why it mattersThe Dahej fire was a major disruption affecting assets worth 42% of annual revenue; successful insurance recovery and plant rebuilding are critical for the company to reach its FY28 revenue target of ₹1,150 crore.
Total Consolidated Loss: ₹362.90 CrTotal Insurance Received to Date: ₹155 CrLoss vs TTM Revenue: 42.1%Pending Insurance Receivable: ₹193.82 CrRebuild Commissioning Date: H1FY27
📅 Short termThe receipt of ₹15 crore provides minor liquidity support, but the stock's high P/E suggests the market has already factored in a successful recovery.
📈 Long termThe structural recovery depends on the H1FY27 commissioning of the new plant; until then, the company relies on interim production shifts and other sites to maintain volumes.
⚠ Risk flags
- Execution risk in the rapid construction of the replacement plant
- Potential shortfall in final insurance settlement vs recognized receivables
- Prolonged business interruption affecting customer relationships
Key Highlights
Received ₹15 crore as the fourth on-account insurance payment on July 16, 2026.
Total insurance claim received to date stands at ₹155 crore against a recognized receivable of ₹348.82 crore.
Total consolidated loss recognized due to the fire is ₹362.90 crore, including property, plant, and inventory.
Replacement plant at Dahej is scheduled for commissioning in H1FY27 to restore lost capacity.
Net financial impact recognized in FY25 was limited to ₹14.08 crore after accounting for expected insurance recovery.
👀 What to Watch
Monitor the H1FY27 commissioning timeline for the Dahej replacement plant and the final settlement of the remaining ₹193.82 crore insurance receivable to ensure cash flow stability.
₹155 Cr total insurance received; Neogen gets ₹15 Cr fourth on-account payment for Dahej fire
Neogen Chemicals has received an additional ₹15 Crore as the fourth on-account insurance payment related to the March 2025 Dahej fire incident. This brings the total recovery to date to ₹155 Crore, against a total recognized consolidated loss of ₹362.90 Crore. The company has already recognized an insurance receivable of ₹348.82 Crore, implying a net financial impact of ₹14.08 Crore accounted for in FY25. While the affected MPP3 facility remains suspended, a replacement plant is on track for commissioning in H1FY27.
Confidence: HIGH
What changedThe company received a further ₹15 Crore cash inflow from insurers and provided an update on the reconstruction progress of its Dahej facility.
Why it mattersThe insurance receivable of ₹348.82 Crore is significant, representing ~40% of TTM revenue; timely recovery and plant reconstruction are vital for meeting the FY28 revenue target of ₹1,150 Crore.
Fourth on-account payment: ₹15 CroreTotal claim received to date: ₹155 CroreInsurance receivable vs TTM Revenue: 40.46%Total claim received vs Net Worth: 18.17%Consolidated loss recognized: ₹362.90 Crore
📅 Short termPositive impact on liquidity as the company receives cash to fund ongoing reconstruction and operations.
📈 Long termThe rebuilding of the MPP3 facility is a structural necessity to restore full production capacity and achieve long-term growth targets in specialty chemicals.
⚠ Risk flags
- Execution risk in plant reconstruction timeline
- Potential for final insurance settlement to differ from recognized receivables
- Business interruption loss not yet fully quantified or accounted for
Key Highlights
₹15 Crore received as the fourth on-account payment on July 16, 2026
₹155 Crore total on-account insurance claim received to date
₹362.90 Crore total consolidated loss recognized due to the fire incident
H1FY27 scheduled for the commissioning of the replacement plant at Dahej SEZ
₹348.82 Crore total consolidated insurance claim receivable recognized by the company
👀 What to Watch
Monitor the execution timeline for the replacement plant commissioning in H1FY27 and the realization of the remaining ₹193.82 Crore insurance receivable.
Neogen Chemicals Q4 FY26 Revenue Up 22% to ₹247 Cr; FY27 Revenue Guidance ₹875-950 Cr
Neogen Chemicals reported a strong Q4 FY26 with revenue growing 22% YoY to ₹247 crore and EBITDA margins holding steady at 17.8%. The company is aggressively expanding into battery materials, with the Pakhajan Phase 2 project cost revised to ₹1,367 crore for completion by March 2027. Management has provided a standalone revenue guidance of ₹875-950 crore for FY27, driven by the commissioning of new facilities. Despite high debt levels of ₹1,330 crore due to capex, the company maintains a positive outlook on the lithium-ion battery ecosystem.
Key Highlights
Q4 FY26 revenue rose 22% YoY to ₹247 crore, while full-year FY26 revenue reached ₹862 crore.
Inorganic Chemicals segment saw a massive 145% YoY expansion in Q4, contributing ₹53 crore.
Pakhajan Phase 2 capex revised to ₹1,367 crore with a target completion of March 2027.
Management expects standalone revenue of ₹875-950 crore in FY27 following plant commissionings.
Total debt increased to ₹1,330 crore to fund the Dahej rebuild and Neogen Ionics expansion.
👀 What to Watch
Investors should monitor the timely commissioning of the Pakhajan and Dahej facilities in FY27, as these are critical for achieving revenue targets. The high debt levels warrant caution, but the strategic shift toward battery materials offers significant long-term growth potential.
Neogen Chemicals Q4 Revenue Up 22% to INR 247 Cr; INR 161 Cr Promoter Infusion & INR 1 Dividend
Neogen Chemicals reported a robust 22% YoY revenue growth in Q4 FY26, reaching INR 247 crore, driven by high plant utilization and volume growth. While PAT surged 373% to INR 11 crore, this was primarily due to a low base from the previous year's fire incident. A significant highlight is the promoter infusion of INR 161 crore at a 17% premium to the SEBI floor price, signaling strong confidence in the company's pivot toward battery materials. Management has provided a standalone revenue guidance of INR 875–950 crore for FY27 as the rebuilt Dahej plant and Pakhajan facility come online.
Key Highlights
Q4 FY26 consolidated revenue grew 22% YoY to INR 247 crore with EBITDA margins sustaining at 17.8%.
Promoter group to infuse INR 161 crore via preferential allotment at INR 1,610 per share, a 17% premium to floor price.
Management guided for FY27 standalone revenue of INR 875–950 crore, aided by the June 2026 commissioning of the Dahej replacement plant.
Battery materials project (Neogen Ionics) total cost revised to INR 1,795 crore with Pakhajan facility commercialization expected in H2 FY27.
Board recommended a final dividend of INR 1 per equity share for the financial year 2025-26.
👀 What to Watch
Investors should view the promoter infusion at a premium as a strong bullish signal for the company's long-term transition into the EV battery supply chain. Key monitorables include the timely commissioning of the Pakhajan Greenfield project and the successful ramp-up of electrolyte sales in FY27.
Neogen Chemicals Q4 FY26 PAT Jumps 373% to ₹11.4 Cr; Promoters to Infuse ₹161 Cr
Neogen Chemicals reported a strong Q4 FY26 with consolidated revenue growing 22% YoY to ₹246.6 crore, supported by high plant utilization. While PAT surged 373% to ₹11.4 crore due to a low base from the previous year's fire incident, the company is aggressively pivoting toward battery chemicals. The Board approved a ₹161 crore capital infusion from promoters at ₹1,610 per share, representing a 17% premium. Management has provided a standalone revenue guidance of ₹875–950 crore for FY27 as major expansion projects at Dahej and Pakhajan near commissioning.
Key Highlights
Consolidated Q4 FY26 Revenue rose 22% YoY to ₹246.6 crore with EBITDA margins at 17.8%.
Promoter group to infuse ₹161 crore via preferential allotment at a 17% premium to the SEBI floor price.
Battery chemicals project cost revised to ₹1,795 crore; Pakhajan Electrolyte plant on track for H1 FY27 commissioning.
Consolidated Net Debt increased significantly to ₹1,295 crore to fund massive CAPEX in Neogen Ionics.
Board recommended a final dividend of ₹1 per equity share for the financial year ended March 31, 2026.
👀 What to Watch
Investors should take confidence from the promoter's capital infusion at a premium, which validates the long-term growth strategy in battery materials. However, closely monitor the debt-to-equity levels and the timely commissioning of the Pakhajan facility in H1 FY27.
Neogen Chemicals Recommends Re. 1 Dividend; Revises NIL Project Cost to Rs. 1,795 Crore
Neogen Chemicals has approved its FY26 audited results and recommended a final dividend of Re. 1 per share. The company announced a significant revision in the project timelines and costs for its subsidiary, Neogen Ionics Limited (NIL), with total costs now projected at Rs. 1,795 crore. These projects in Dahej and Pakhajan are now expected to be completed by February and March 2027, respectively, due to a shift to Japanese technology and increased localization. Additionally, the company has recovered Rs. 140 crore of its insurance claim from a 2025 fire incident, with Rs. 188.96 crore still outstanding.
Key Highlights
Recommended a final dividend of Re. 1 per equity share for the financial year 2025-26.
Revised total project cost for Neogen Ionics Limited (NIL) to Rs. 1,795 crore (Dahej: Rs. 428 Cr, Pakhajan: Rs. 1,367 Cr).
Project timelines for NIL extended to Feb/Mar 2027 due to design optimization and adoption of Japanese technology.
Outstanding insurance claim receivable stands at Rs. 188.96 crore as of March 31, 2026.
Funding for additional capex to be met through promoter equity infusion and planned JV partner contributions.
👀 What to Watch
Investors should monitor the execution of the Neogen Ionics project as the timeline has shifted to 2027 with increased costs. The successful recovery of the remaining Rs. 188.96 crore insurance claim remains a critical factor for the company's cash flow.
Neogen Chemicals Recommends ₹1 Dividend; Updates ₹1,795 Cr Project Timelines
Neogen Chemicals has recommended a final dividend of ₹1 per equity share for FY 2025-26. The company reported a significant update for its subsidiary, Neogen Ionics, revising the total project cost for Dahej and Pakhajan to ₹1,795 crore with completion timelines now set for early 2027. The Dahej Phase 1 project was delayed to February 2027 due to a shift to Japanese technology and design optimizations. Additionally, the company is still awaiting ₹188.96 crore in insurance claims following a major fire incident in March 2025.
Key Highlights
Recommended a final dividend of ₹1 per equity share for the financial year ended March 31, 2026.
Revised total project cost for Neogen Ionics Limited (NIL) to ₹1,795 crore (₹428 Cr for Dahej and ₹1,367 Cr for Pakhajan).
Dahej Phase 1 timeline extended to February 2027 due to technology changeover and higher localization efforts.
Outstanding insurance claim receivable stands at ₹188.96 crore after receiving ₹140 crore on-account payment.
Auditors issued an unmodified opinion on the audited standalone and consolidated financial results for FY26.
👀 What to Watch
Investors should focus on the execution of the Neogen Ionics expansion as the shift to Japanese technology and revised timelines may delay revenue realization. Monitor the recovery of the remaining insurance claim as it will impact cash flows and liquidity.
Neogen Chemicals FY26 Results: Re. 1 Dividend Declared and ₹1,795 Cr Project Update
Neogen Chemicals has approved its audited financial results for FY26 and recommended a final dividend of ₹1 per share. A significant update was provided regarding its subsidiary, Neogen Ionics, where the total project cost for Dahej and Pakhajan facilities has been revised to ₹1,795 crore with completion now expected in early 2027. The company continues to pursue an insurance claim of ₹188.96 crore following a 2025 fire incident, having received ₹140 crore to date. The project delays and cost increases are attributed to a strategic shift toward Japanese technology and increased localization.
Key Highlights
Recommended a final dividend of ₹1 per equity share for the financial year 2025-26.
Revised total project cost for Neogen Ionics (Dahej & Pakhajan) to ₹1,795 crore from previous estimates.
Project timelines for Phase 1 and Phase 2 extended to February and March 2027 respectively.
Outstanding insurance claim receivable stands at ₹188.96 crore as of March 31, 2026.
Additional capex to be funded via promoter equity infusion and planned JV partner contributions.
👀 What to Watch
Investors should monitor the execution of the Neogen Ionics project as the shift to Japanese technology may enhance long-term competitiveness despite current delays. The successful recovery of the remaining ₹189 crore insurance claim will be a critical factor for cash flow in the coming quarters.
Neogen Chemicals Subsidiary to Invest ₹100.11 Cr in Step-Down Subsidiary for EV Battery Materials
Neogen Chemicals' wholly-owned subsidiary, Neogen Ionics Limited (NIL), has approved an investment of ₹100.11 crore in its step-down subsidiary, Neogen Morita New Material Limited (NML). The investment will be executed through a rights issue of 71,00,000 equity shares at a price of ₹141 per share. This capital infusion is specifically targeted at the Lithium-Ion Battery material space, focusing on electrolyte salts for both internal consumption and global markets. The move signifies Neogen's aggressive expansion into the electric vehicle supply chain ecosystem.
Key Highlights
Investment of ₹100.11 crore via rights issue in step-down subsidiary Neogen Morita New Material Limited (NML).
Subscription of 71,00,000 equity shares at ₹141 per share (including a premium of ₹131).
NML's authorized share capital increased from ₹5 crore to ₹9.9 crore to accommodate the issuance.
Funds earmarked for acquiring salt business, CAPEX, and OPEX requirements for Lithium-Ion Battery materials.
The transaction is expected to be completed within 60 days of receipt of share application money.
👀 What to Watch
Investors should monitor the progress of the Lithium-Ion Battery material project as it represents a high-growth vertical for the company. While the investment is strategic, the long-term impact will depend on the successful execution of CAPEX and market adoption of their electrolyte salts.
Neogen Chemicals Allots 10 Lakh Shares to Promoter Group for Rs 161 Crore
Neogen Chemicals has completed a preferential allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a member of the promoter group. The allotment was executed at a price of Rs. 1,610 per share (including a premium of Rs. 1,600), resulting in a total capital infusion of Rs. 161 crore. This transaction increases the promoter group's holding, with this specific entity now owning 3.65% of the post-allotment paid-up capital. Such a significant investment by promoters at a premium is generally viewed as a strong signal of confidence in the company's future growth.
Key Highlights
Allotment of 10,00,000 equity shares at an issue price of Rs. 1,610 per share
Total investment amount aggregates to Rs. 161 crore for cash consideration
Acquisition constitutes 3.65% of the post-allotment paid-up equity capital
Total paid-up equity capital increased from Rs. 26.38 crore to Rs. 27.38 crore
The acquirer, Cadamba Solutions Private Limited, belongs to the promoter group
👀 What to Watch
Investors should take this as a positive indicator of promoter commitment and confidence in the company's valuation. Monitor the company's upcoming quarterly results to see how this additional capital is deployed for expansion.
Neogen Chemicals Promoter Group Acquires 10 Lakh Shares via Preferential Allotment for ₹161 Cr
Neogen Chemicals has successfully completed a preferential allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a member of the promoter group. The shares were issued at a price of ₹1,610 per share, resulting in a total capital infusion of ₹161 crores into the company. This transaction gives the promoter group entity a 3.65% stake in the expanded post-allotment equity capital. Such significant investment by the promoter group is generally viewed as a strong signal of confidence in the company's valuation and future growth prospects.
Key Highlights
Allotment of 10,00,000 equity shares at an issue price of ₹1,610 per share
Total capital infusion of ₹161 crores by promoter group entity Cadamba Solutions
Acquirer's stake represents 3.65% of the post-allotment paid-up equity capital
Total paid-up equity capital increased from ₹26.38 crore to ₹27.38 crore
The allotment was finalized on April 18, 2026, following regulatory compliance
👀 What to Watch
Investors should take note of the promoter group's commitment at the ₹1,610 price point, which serves as a positive valuation benchmark. The capital infusion strengthens the balance sheet and supports future expansion plans.
Neogen Chemicals Allots 10 Lakh Shares to Promoter Group for Rs 161 Crore
Neogen Chemicals has completed a preferential allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a member of the promoter group. The shares were issued at a price of Rs. 1,610 per share, resulting in a total capital infusion of Rs. 161 crore into the company. This transaction increases the promoter entity's stake to 3.65% of the post-allotment paid-up capital. Such significant capital infusion by promoters at a premium typically signals strong internal confidence in the company's long-term growth and valuation.
Key Highlights
Allotment of 10,00,000 equity shares to promoter group entity Cadamba Solutions Private Limited.
Issue price set at Rs. 1,610 per share, including a premium of Rs. 1,600 per share.
Total capital raised through this preferential allotment amounts to Rs. 161 crore.
The acquisition constitutes 3.65% of the post-allotment paid-up equity capital of the company.
Total paid-up equity capital increased from Rs. 26.38 crore to Rs. 27.38 crore following the allotment.
👀 What to Watch
Investors should view this promoter-led capital infusion as a positive indicator of commitment and confidence in the company's future. Monitor the company's upcoming quarterly results to see how this additional capital is deployed for expansion or debt management.
Neogen Chemicals Promoter Group Acquires 10 Lakh Shares for ₹161 Cr via Preferential Allotment
Cadamba Solutions Private Limited, a promoter group entity, has acquired 10 lakh equity shares of Neogen Chemicals at ₹1,610 per share. The total transaction value is ₹161 crores, executed via a preferential allotment on April 18, 2026. This acquisition results in the promoter group entity holding a 3.65% stake in the expanded post-allotment capital. Such capital infusion by promoters is usually viewed as a strong vote of confidence in the company's future valuation and strategic direction.
Key Highlights
10,00,000 equity shares allotted to Cadamba Solutions Private Limited (Promoter Group)
Issue price set at ₹1,610 per share, including a premium of ₹1,600
Total capital infusion of ₹161 crores into the company for cash consideration
Post-allotment paid-up equity capital increased to 2,73,81,674 shares from 2,63,81,674 shares
The acquisition constitutes 3.65% of the post-allotment paid-up equity capital
👀 What to Watch
The promoter's decision to invest ₹161 crores at ₹1,610 per share provides a strong valuation benchmark and indicates long-term commitment; investors should view this as a positive signal for the company's growth prospects.
Neogen Chemicals Allots 10 Lakh Equity Shares to Promoter Group, Raising Rs. 161 Crore
Neogen Chemicals has completed the allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a promoter group entity, on a preferential basis. The shares were issued at a price of Rs. 1,610 per share, which is a significant 17.02% premium over the regulatory floor price of Rs. 1,375.82. This move has successfully raised Rs. 161 crore for the company, increasing its paid-up equity capital to Rs. 27.38 crore. The infusion of capital by the promoter group at a premium indicates strong internal confidence in the company's future prospects.
Key Highlights
Allotted 10,00,000 equity shares at Rs. 1,610 per share, aggregating to Rs. 161 crore
Issue price of Rs. 1,610 is 17.02% higher than the SEBI floor price of Rs. 1,375.82
The entire allotment was made to Cadamba Solutions Private Limited, a Promoter Group member
Paid-up equity share capital increased from Rs. 26.38 crore to Rs. 27.38 crore
Allotted shares are subject to a lock-in period of 18 months as per SEBI ICDR Regulations
👀 What to Watch
Investors should take this as a positive signal of promoter commitment and financial backing at a premium valuation. Monitor the company's upcoming quarterly results to see how this capital infusion is deployed for growth initiatives.
Neogen Chemicals Allots 10 Lakh Equity Shares to Promoter Group for Rs 161 Crore
Neogen Chemicals has completed the allotment of 10,00,000 equity shares to Cadamba Solutions Private Limited, a member of the promoter group. The shares were issued at a price of Rs 1,610 per share, which is a significant 17.02% premium over the regulatory floor price of Rs 1,375.82. This preferential issue has successfully raised Rs 161 crore, strengthening the company's capital base. Post-allotment, the company's paid-up equity share capital has increased to Rs 27.38 crore.
Key Highlights
Allotment of 10,00,000 equity shares at a price of Rs 1,610 per share
Total fundraise of Rs 161 crore from a promoter group entity
Issue price represents a 17.02% premium over the floor price of Rs 1,375.82
Paid-up equity capital increased from Rs 26.38 crore to Rs 27.38 crore
Allotted shares are subject to a lock-in period of 18 months
👀 What to Watch
The promoter group's decision to infuse capital at a premium to the floor price signals strong internal confidence in the company's valuation and growth prospects. Investors should view this as a positive development for long-term capital structure and liquidity.
Neogen Chemicals Promoter Discloses Pledge of 13.19 Lakh Equity Shares
Dr. Harin Kanani, representing the Haridas Kanani Family Trust, has submitted a mandatory annual declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The disclosure confirms that the promoter group maintained its shares without encumbrance for most of the year, except for a specific pledge. On March 30, 2026, a pledge was created on 13,19,083 equity shares held by Dr. Harin Kanani. This filing ensures transparency regarding promoter shareholding and any potential liens on their stake.
Key Highlights
Pledge created on 13,19,083 equity shares of Neogen Chemicals Limited
Encumbrance was established by Dr. Harin Kanani on March 30, 2026
Declaration filed under Regulation 31(4) of SEBI (SAST) Regulations, 2011
No other creation, invocation, or release of encumbrance occurred during FY 2025-26
👀 What to Watch
Investors should monitor the total percentage of promoter equity now pledged to assess any potential risk of margin calls. While pledging is a common financing tool, a significant increase in encumbered shares can impact market sentiment.
Neogen Chemicals Promoter Dr. Harin Haridas Kanani Pledges 13.19 Lakh Shares
Dr. Harin Haridas Kanani, a promoter of Neogen Chemicals Limited, has disclosed the creation of a pledge on 13,19,083 equity shares as of March 30, 2026. This disclosure, made under SEBI (SAST) Regulations, confirms that this was the only encumbrance activity by the promoter group during the financial year ended March 31, 2026. While pledging is a common financial tool, it is closely watched by investors as it involves using company ownership as collateral. The filing ensures transparency regarding the promoter's shareholding status at the end of the fiscal year.
Key Highlights
Promoter Dr. Harin Haridas Kanani created an encumbrance on 13,19,083 equity shares.
The pledge was created on March 30, 2026, just before the financial year-end.
Disclosure confirms no other promoter or PAC created, invoked, or released pledges in FY 2025-26.
The filing was submitted in compliance with Regulation 31(4) of SEBI Takeover Regulations.
👀 What to Watch
Investors should monitor the total percentage of promoter holding pledged to evaluate potential margin call risks. It is important to verify if the pledge was for personal liquidity or to support company growth initiatives.
